Responses
Regular and Young Investigator Award Abstracts
Clinical Trials Completed
353 Identification of potential response predictors to maveropepimut-S (DPX-Survivac), a novel T cell activating immunotherapy, in patients with advanced recurrent ovarian cancer
Compose a Response to This Article
Other responses
No responses have been published for this article.